Literature DB >> 30803823

mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases.

Giulietta Maruggi1, Cuiling Zhang2, Junwei Li2, Jeffrey B Ulmer3, Dong Yu4.   

Abstract

In the last two decades, there has been growing interest in mRNA-based technology for the development of prophylactic vaccines against infectious diseases. Technological advancements in RNA biology, chemistry, stability, and delivery systems have accelerated the development of fully synthetic mRNA vaccines. Potent, long-lasting, and safe immune responses observed in animal models, as well as encouraging data from early human clinical trials, make mRNA-based vaccination an attractive alternative to conventional vaccine approaches. Thanks to these data, together with the potential for generic, low-cost manufacturing processes and the completely synthetic nature, the prospects for mRNA vaccines are very promising. In addition, mRNA vaccines have the potential to streamline vaccine discovery and development, and facilitate a rapid response to emerging infectious diseases. In this review, we overview the unique attributes of mRNA vaccine approaches, review the data of mRNA vaccines against infectious diseases, discuss the current challenges, and highlight perspectives about the future of this promising technology.
Copyright © 2019 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  RNA-based vaccine; infectious diseases; self-amplifying mRNA; synthetic vaccine; vaccine on demand

Year:  2019        PMID: 30803823      PMCID: PMC6453507          DOI: 10.1016/j.ymthe.2019.01.020

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  163 in total

1.  Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA.

Authors:  Katalin Karikó; Michael Buckstein; Houping Ni; Drew Weissman
Journal:  Immunity       Date:  2005-08       Impact factor: 31.745

2.  Blocking monoclonal antibodies specific for mouse IFN-alpha/beta receptor subunit 1 (IFNAR-1) from mice immunized by in vivo hydrodynamic transfection.

Authors:  Kathleen C F Sheehan; Koon Siew Lai; Gavin P Dunn; Allen T Bruce; Mark S Diamond; Jennifer D Heutel; Corazon Dungo-Arthur; Javier A Carrero; J Michael White; Paul J Hertzog; Robert D Schreiber
Journal:  J Interferon Cytokine Res       Date:  2006-11       Impact factor: 2.607

Review 3.  Role of 5'- and 3'-untranslated regions of mRNAs in human diseases.

Authors:  Sangeeta Chatterjee; Jayanta K Pal
Journal:  Biol Cell       Date:  2009-05       Impact factor: 4.458

4.  Vaccine Mediated Protection Against Zika Virus-Induced Congenital Disease.

Authors:  Justin M Richner; Brett W Jagger; Chao Shan; Camila R Fontes; Kimberly A Dowd; Bin Cao; Sunny Himansu; Elizabeth A Caine; Bruno T D Nunes; Daniele B A Medeiros; Antonio E Muruato; Bryant M Foreman; Huanle Luo; Tian Wang; Alan D Barrett; Scott C Weaver; Pedro F C Vasconcelos; Shannan L Rossi; Giuseppe Ciaramella; Indira U Mysorekar; Theodore C Pierson; Pei-Yong Shi; Michael S Diamond
Journal:  Cell       Date:  2017-07-13       Impact factor: 41.582

5.  The 'anti-hype' vaccine.

Authors:  Laura DeFrancesco
Journal:  Nat Biotechnol       Date:  2017-02-27       Impact factor: 54.908

Review 6.  Biology and application of alphaviruses in gene therapy.

Authors:  K Lundstrom
Journal:  Gene Ther       Date:  2005-10       Impact factor: 5.250

7.  Mechanism for control of synthesis of Semliki Forest virus 26S and 42s RNA.

Authors:  D L Sawicki; L Kaariainen; C Lambek; P J Gomatos
Journal:  J Virol       Date:  1978-01       Impact factor: 5.103

8.  Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity.

Authors:  Shinu John; Olga Yuzhakov; Angela Woods; Jessica Deterling; Kimberly Hassett; Christine A Shaw; Giuseppe Ciaramella
Journal:  Vaccine       Date:  2018-02-15       Impact factor: 3.641

9.  Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin.

Authors:  Katalin Karikó; Hiromi Muramatsu; Jason M Keller; Drew Weissman
Journal:  Mol Ther       Date:  2012-02-14       Impact factor: 11.454

Review 10.  A novel, disruptive vaccination technology: self-adjuvanted RNActive(®) vaccines.

Authors:  Karl-Josef Kallen; Regina Heidenreich; Margit Schnee; Benjamin Petsch; Thomas Schlake; Andreas Thess; Patrick Baumhof; Birgit Scheel; Sven D Koch; Mariola Fotin-Mleczek
Journal:  Hum Vaccin Immunother       Date:  2013-06-04       Impact factor: 3.452

View more
  108 in total

Review 1.  Comparison of DNA and mRNA vaccines against cancer.

Authors:  Zohreh Jahanafrooz; Behzad Baradaran; Jafar Mosafer; Mahmoud Hashemzaei; Tayebeh Rezaei; Ahad Mokhtarzadeh; Michael R Hamblin
Journal:  Drug Discov Today       Date:  2019-12-13       Impact factor: 7.851

2.  Formulation and Delivery Technologies for mRNA Vaccines.

Authors:  Chunxi Zeng; Chengxiang Zhang; Patrick G Walker; Yizhou Dong
Journal:  Curr Top Microbiol Immunol       Date:  2020-06-02       Impact factor: 4.291

Review 3.  Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019 (COVID-19), a comprehensive literature review.

Authors:  Esteban Ortiz-Prado; Katherine Simbaña-Rivera; Lenin Gómez-Barreno; Mario Rubio-Neira; Linda P Guaman; Nikolaos C Kyriakidis; Claire Muslin; Ana María Gómez Jaramillo; Carlos Barba-Ostria; Doménica Cevallos-Robalino; Hugo Sanches-SanMiguel; Luis Unigarro; Rasa Zalakeviciute; Naomi Gadian; Andrés López-Cortés
Journal:  Diagn Microbiol Infect Dis       Date:  2020-05-30       Impact factor: 2.803

4.  Incomplete Subacute Transverse Myelitis Following Vaccination With Pfizer-BioNTech COVID-19 mRNA Vaccine: A Case Report.

Authors:  Jarrah Alabkal; Alexander D Rebchuk; Daniel Lyndon; Nikkie Randhawa
Journal:  Cureus       Date:  2021-12-16

5.  BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans.

Authors:  Ugur Sahin; Alexander Muik; Isabel Vogler; Evelyna Derhovanessian; Lena M Kranz; Mathias Vormehr; Jasmin Quandt; Nicole Bidmon; Alexander Ulges; Alina Baum; Kristen E Pascal; Daniel Maurus; Sebastian Brachtendorf; Verena Lörks; Julian Sikorski; Peter Koch; Rolf Hilker; Dirk Becker; Ann-Kathrin Eller; Jan Grützner; Manuel Tonigold; Carsten Boesler; Corinna Rosenbaum; Ludwig Heesen; Marie-Cristine Kühnle; Asaf Poran; Jesse Z Dong; Ulrich Luxemburger; Alexandra Kemmer-Brück; David Langer; Martin Bexon; Stefanie Bolte; Tania Palanche; Armin Schultz; Sybille Baumann; Azita J Mahiny; Gábor Boros; Jonas Reinholz; Gábor T Szabó; Katalin Karikó; Pei-Yong Shi; Camila Fontes-Garfias; John L Perez; Mark Cutler; David Cooper; Christos A Kyratsous; Philip R Dormitzer; Kathrin U Jansen; Özlem Türeci
Journal:  Nature       Date:  2021-05-27       Impact factor: 49.962

Review 6.  Integrating Biomaterials and Immunology to Improve Vaccines Against Infectious Diseases.

Authors:  Lampouguin Yenkoidiok-Douti; Christopher M Jewell
Journal:  ACS Biomater Sci Eng       Date:  2020-01-12

Review 7.  mRNA-Based Vaccines.

Authors:  Frank Kowalzik; Daniel Schreiner; Christian Jensen; Daniel Teschner; Stephan Gehring; Fred Zepp
Journal:  Vaccines (Basel)       Date:  2021-04-15

8.  mRNA therapy restores euglycemia and prevents liver tumors in murine model of glycogen storage disease.

Authors:  Jingsong Cao; Minjung Choi; Eleonora Guadagnin; Maud Soty; Marine Silva; Vincent Verzieux; Edward Weisser; Arianna Markel; Jenny Zhuo; Shi Liang; Ling Yin; Andrea Frassetto; Anne-Renee Graham; Kristine Burke; Tatiana Ketova; Cosmin Mihai; Zach Zalinger; Becca Levy; Gilles Besin; Meredith Wolfrom; Barbara Tran; Christopher Tunkey; Erik Owen; Joe Sarkis; Athanasios Dousis; Vladimir Presnyak; Christopher Pepin; Wei Zheng; Lei Ci; Marjie Hard; Edward Miracco; Lisa Rice; Vi Nguyen; Mike Zimmer; Uma Rajarajacholan; Patrick F Finn; Gilles Mithieux; Fabienne Rajas; Paolo G V Martini; Paloma H Giangrande
Journal:  Nat Commun       Date:  2021-05-25       Impact factor: 14.919

9.  Methodological Analysis: Randomized Controlled Trials for Pfizer and Moderna COVID-19 Vaccines.

Authors:  Donna Hallas; Regena Spratling; Jason Fletcher
Journal:  J Pediatr Health Care       Date:  2021-05-31       Impact factor: 1.838

Review 10.  Synthetic modified messenger RNA for therapeutic applications.

Authors:  Minsong Gao; Qingyi Zhang; Xin-Hua Feng; Jianzhao Liu
Journal:  Acta Biomater       Date:  2021-06-13       Impact factor: 8.947

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.